Program Schedule — Pacific Time
11:00 AM – 11:30 AM — Registration and Lunch
11:30 AM – 1:30 PM — Educational Meeting
Location
Manchester Grand Hyatt San Diego
1 Market Place
San Diego, California
Meeting Room
Seaport E-H (Second Level)
This event will also be webcast live. Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Diego, preregistration is required as seating is limited.
Faculty Prithviraj Bose, MD
Professor, Department of Leukemia
Co-Leader, Section of Myeloproliferative Neoplasms
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Angela G Fleischman, MD, PhD
Associate Professor
Department of Medicine Division of Hematology/Oncology
UC Irvine Health
Irvine, California
Abdulraheem Yacoub, MD
Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapeutics (HMCT)
Department of Internal Medicine
The University of Kansas Cancer Center
Westwood, Kansas
Moderator Andrew T Kuykendall, MD
Associate Member Department of Malignant Hematology
Moffitt Cancer Center
Associate Professor Department of Oncologic Sciences
University of South Florida
Tampa, Florida
This activity is supported by educational grants from CTI BioPharma, a Sobi Company, Geron Corporation, GSK, Incyte Corporation, and Karyopharm Therapeutics.
Program Schedule — Pacific Time
11:00 AM – 11:30 AM — Registration and Lunch
11:30 AM – 1:30 PM — Educational Meeting
MODULE 1: Current Clinical Decision-Making for Myelofibrosis (MF) in the Absence of Severe Cytopenias — Dr Kuykendall
Factors influencing the initiation and choice of therapy for patients with MF without severe cytopenias
Published research database supporting the use of ruxolitinib for intermediate- and high-risk MF; impact of ruxolitinib on symptom control and survival
Key efficacy and safety findings with fedratinib for patients with newly diagnosed MF and those resistant or intolerant to ruxolitinib; selection of individuals for treatment with fedratinib
Initial dosing and dose-modification strategies for ruxolitinib and fedratinib
Spectrum, frequency and severity of common and unique toxicities associated with ruxolitinib and fedratinib; optimal approach to monitoring and management of treatment-related adverse events (AEs)
MODULE 2: Managing MF for Patients with Thrombocytopenia — Dr Bose
Incidence of thrombocytopenia in patients with newly diagnosed MF and in those with prior JAK inhibitor exposure
Mechanistic similarities and differences between pacritinib and other approved JAK inhibitors; implications for the safety of pacritinib for patients with low platelet counts
Published clinical research findings with pacritinib for MF, including among patients with baseline thrombocytopenia
FDA approval of pacritinib for patients with MF and severe thrombocytopenia; optimal use in clinical practice and ongoing investigation (eg, Phase III PACIFICA study)
Incidence and severity of treatment-related AEs, including hemorrhage and cardiovascular events, reported with pacritinib; optimal monitoring and management paradigms
MODULE 3: Managing MF for Patients with Anemia — Dr Yacoub
Rationale for the activity of momelotinib in patients with MF and anemia; differences between momelotinib and other approved JAK inhibitors
Key findings from the Phase III MOMENTUM study of momelotinib versus danazol for symptomatic, anemic patients previously treated with a JAK inhibitor
Efficacy and safety of momelotinib compared to ruxolitinib in the subset of patients with JAK inhibitor-naïve disease and anemia in the Phase III SIMPLIFY-1 trial
FDA approval of momelotinib for patients with MF and anemia; current role in disease management
Comparative tolerability/toxicity profile of momelotinib versus other approved JAK inhibitors
Retrospective analysis of the PERSIST-2 study to evaluate the utility of pacritinib for patients with MF and anemia; role, if any, of pacritinib in this setting
Mechanism of action of, available data with and ongoing evaluation of luspatercept as monotherapy or combined with a JAK inhibitor for patients with MF and anemia
MODULE 4: Future Directions in the Management of MF — Dr Fleischman
Mechanism of antitumor activity of navitoclax and biological rationale for its evaluation for MF
Available efficacy and safety findings from the Phase III TRANSFORM-1 study of
navitoclax in combination with ruxolitinib versus ruxolitinib alone for patients with previously untreated MF
Rationale for the evaluation of BET inhibitors for MF; updated findings from the Phase III MANIFEST-2 study combining pelabresib with ruxolitinib for JAK inhibitor-naïve disease
Scientific justification for the evaluation of selinexor for MF; early efficacy and safety findings with selinexor as monotherapy and in combination with ruxolitinib
Ongoing evaluation of the combination of selinexor and ruxolitinib for JAK inhibitor-naïve disease in the Phase III XPORT-MF-034 trial; estimated study completion date
Mechanism of action of imetelstat; key findings from the Phase II IMbark trial of imetelstat monotherapy for relapsed/refractory (R/R) MF
Design, eligibility criteria and key endpoints of the Phase III IMpactMF study comparing imetelstat to best available therapy for R/R MF
Other promising investigational agents and strategies (eg, zilurgisertib, navtemadlin) for MF
Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of myelofibrosis (MF).
Learning Objectives
Upon completion of this activity, participants should be able to
Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with MF regarding their long-term prognosis.
Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for primary and secondary MF.
Appraise available research findings informing the safety and efficacy of approved JAK inhibitors for patients with MF.
Review available research data with and the current clinical role of next-generation JAK inhibitors for patients with MF and severe thrombocytopenia.
Evaluate published research findings with the use of JAK inhibitors for patients with MF and anemia to optimize decision-making for this population.
Assess available research findings with novel therapies and combination regimens incorporating JAK inhibitors, and consider the potential clinical application of these approaches.
Increase participation in active research protocols by counseling appropriately selected patients regarding the biological rationale for and available efficacy and safety data with novel investigational agents and strategies for MF.
CE Credit
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY
— The following faculty reported relevant financial relationships with ineligible entities:
Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by educational grants from CTI BioPharma, a Sobi Company, Geron Corporation, GSK, Incyte Corporation, and Karyopharm Therapeutics.
Manchester Grand Hyatt San Diego
1 Market Place
San Diego, CA 92101
Meeting Room
Seaport E-H (Second Level)
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of myelofibrosis.
There is no fee to participate in this hybrid event. In order to attend the in-person symposium in San Diego, you must also be registered to attend the ASH 2024 Annual Meeting. Preregistration (below) is required as seating is limited for this program.
IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.
